United Therapeutics Corp (NASDAQ: UTHR) Chairperson and CEO Martine A. Rothblatt has finalized a transaction involving the sale of common stock valued at roughly $5.44 million. This divestment, which occurred on April 30, 2026, was conducted in conjunction with the exercise of stock options through a pre-arranged trading schedule.
According to regulatory filings, Ms. Rothblatt disposed of 9,500 shares of United Therapeutics common stock. The sale was executed at various price points ranging from $569.08 to $579.51 per share, culminating in a total transaction value of $5,439,990. At the time of reporting, UTHR shares were trading at $570.06, which is positioned near the 52-week high of $607.89. This price level reflects a substantial 94% increase in share value over the preceding year. However, analysis from InvestingPro suggests that the current stock valuation may be overvalued.
Transaction Details and Trading Framework
The sale was preceded by an acquisition of 9,500 shares through the exercise of stock options on the same day. These options were acquired at a price of $146.03 per share, representing a total cost of $1,387,285. The specific options involved in this transaction were originally granted to Ms. Rothblatt on March 15, 2020, and are scheduled to expire on March 15, 2027.
Both the acquisition via option exercise and the subsequent sale of common stock were performed under a Rule 10b5-1 trading plan. This specific plan was adopted by Ms. Rothblatt on November 7, 2025. The framework of this plan dictates that it will remain in effect until either December 31, 2026, is reached, or until a total of 1,734,410 stock options have been exercised, whichever milestone occurs first.
Following these specific transactions, Ms. Rothblatt maintains a direct holding of 40,513 shares of United Therapeutics common stock. Furthermore, she holds an indirect interest in 639,284 shares through various family trusts and her spouse. These indirect holdings encompass shares where Ms. Rothblatt possesses investment power, or instances where her spouse acts as a trustee or beneficiary, or where Ms. Rothblatt herself serves as a trustee or beneficiary.
Clinical and Research Advancements
United Therapeutics continues to advance its clinical portfolio. The U.S. Food and Drug Administration (FDA) recently granted Regenerative Medicine Advanced Therapy designation to the company's investigational liver device, miroliverELAP. This device is intended to provide temporary support for the livers of patients suffering from acute liver failure.
In addition to regulatory milestones, the corporation is prepared to share significant research findings at the International Society for Heart and Lung Transplantation’s annual meeting. The company plans to present 11 different data presentations, which include interim analyses from studies such as ARTISAN and PHINDER. These studies are centered on treatments for arterial hypertension and pulmonary hypertension.
Market Outlook and Analyst Sentiment
Financial institutions have recently updated their outlooks on United Therapeutics following positive clinical data. Raymond James has initiated coverage with an Outperform rating and a price target of $700, citing the potential peak sales for Tyvaso in cases of idiopathic pulmonary fibrosis. Similarly, H.C. Wainwright maintained a Buy rating while raising its price target to $660, pointing toward robust data from the TETON-1 trial.
BofA Securities also adjusted its projections upward, setting a price target of $626. This revision followed positive results from the Phase 3 TETON-1 trial, which provided confirmation regarding the efficacy of Tyvaso in treating idiopathic pulmonary fibrosis.